Incorporating patient-preference evidence into regulatory decision making.

Autor: Ho MP; Center for Devices and Radiological Health, U.S. Food and Drug Administration, 10903 New Hampshire Ave, Building 66, Room 2232, Silver Spring, MD, 20993-0002, USA. martin.ho@fda.hhs.gov., Gonzalez JM; RTI Health Solutions, Durham, USA. jgonzalez@rti.org., Lerner HP; Center for Devices and Radiological Health, U.S. Food and Drug Administration, 10903 New Hampshire Ave, Building 66, Room 2232, Silver Spring, MD, 20993-0002, USA. herbert.lerner@fda.hhs.gov., Neuland CY; Center for Devices and Radiological Health, U.S. Food and Drug Administration, 10903 New Hampshire Ave, Building 66, Room 2232, Silver Spring, MD, 20993-0002, USA. carolyn.neuland@fda.hhs.gov., Whang JM; Center for Devices and Radiological Health, U.S. Food and Drug Administration, 10903 New Hampshire Ave, Building 66, Room 2232, Silver Spring, MD, 20993-0002, USA. joyce.whang@fda.hhs.gov., McMurry-Heath M; Center for Devices and Radiological Health, U.S. Food and Drug Administration, 10903 New Hampshire Ave, Building 66, Room 2232, Silver Spring, MD, 20993-0002, USA. michelle.mcmurry-heath@fda.hhs.gov.; FaegreBD Consulting, Washington, USA. michelle.mcmurry-heath@fda.hhs.gov., Hauber AB; RTI Health Solutions, Durham, USA. abhauber@rti.org., Irony T; Center for Devices and Radiological Health, U.S. Food and Drug Administration, 10903 New Hampshire Ave, Building 66, Room 2232, Silver Spring, MD, 20993-0002, USA. telba.irony@fda.hhs.gov.
Jazyk: angličtina
Zdroj: Surgical endoscopy [Surg Endosc] 2015 Oct; Vol. 29 (10), pp. 2984-93. Date of Electronic Publication: 2015 Jan 01.
DOI: 10.1007/s00464-014-4044-2
Abstrakt: Background: Patients have a unique role in deciding what treatments should be available for them and regulatory agencies should take their preferences into account when making treatment approval decisions. This is the first study designed to obtain quantitative patient-preference evidence to inform regulatory approval decisions by the Food and Drug Administration Center for Devices and Radiological Health.
Methods: Five-hundred and forty United States adults with body mass index (BMI) ≥ 30 kg/m(2) evaluated tradeoffs among effectiveness, safety, and other attributes of weight-loss devices in a scientific survey. Discrete-choice experiments were used to quantify the importance of safety, effectiveness, and other attributes of weight-loss devices to obese respondents. A tool based on these measures is being used to inform benefit-risk assessments for premarket approval of medical devices.
Results: Respondent choices yielded preference scores indicating their relative value for attributes of weight-loss devices in this study. We developed a tool to estimate the minimum weight loss acceptable by a patient to receive a device with a given risk profile and the maximum mortality risk tolerable in exchange for a given weight loss. For example, to accept a device with 0.01 % mortality risk, a risk tolerant patient will require about 10 % total body weight loss lasting 5 years.
Conclusions: Patient preference evidence was used make regulatory decision making more patient-centered. In addition, we captured the heterogeneity of patient preferences allowing market approval of effective devices for risk tolerant patients. CDRH is using the study tool to define minimum clinical effectiveness to evaluate new weight-loss devices. The methods presented can be applied to a wide variety of medical products. This study supports the ongoing development of a guidance document on incorporating patient preferences into medical-device premarket approval decisions.
Databáze: MEDLINE
Externí odkaz: